Market Overview

UPDATE: Ascendiant Capital Upgrades PhotoMedex to Strong Buy on Attractive Entry Point

Related PHMD
20 Biggest Mid-Day Gainers For Wednesday
Mid-Day Market Update: Twilio Tumbles On Weak Guidance; Pieris Pharma Shares Climb

Ascendiant Capital raised its rating on PhotoMedex (NASDAQ: PHMD) from Buy to Strong Buy with a reiterated $18 price target.

Ascendiant Capital noted, "Revenue was $56.7 MM (+63% yoy), which was below our and consensus estimates of $58.0 MM and $58.7 MM respectively. Pro forma revenue growth was +32%. GAAP EPS was $0.35, significantly higher than the consensus estimate of $0.28 and our estimate of $0.29. … In our opinion, the recent weakness in the stock has created an attractive entry point. Hence, we are upgrading our rating to Strong Buy. Our 12-month price target of $18 represents a target forward EV/EBITDAS ratio of 6.8x our FY13 estimate of $49.4 MM."

PhotoMedex closed at $12.06 on Wednesday.

Latest Ratings for PHMD

Nov 2014Canaccord GenuityMaintainsHold
Aug 2014Canaccord GenuityDowngradesBuyHold
May 2014AscendiantDowngradesBuyHold

View More Analyst Ratings for PHMD
View the Latest Analyst Ratings

Posted-In: Ascendiant CapitalAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Related Articles (PHMD)

View Comments and Join the Discussion!